Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517049 | 0.88 | DPP7 (0.41) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL31146508 | 0.86 | DPP7 (0.43) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL29608892 | 0.86 | DPP7 (0.42) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL27740315 | 0.85 | PTGS1 (0.43) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL27740313 | 0.85 | PTGS1 (0.43) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL30448973 | 0.84 | MEN1 (0.46) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL27212654 | 0.84 | MEN1 (0.46) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL27212749 | 0.84 | MEN1 (0.46) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL29630616 | 0.84 | MEN1 (0.41) | DPP7CTSCMEN1KMT2APRCP | |
| SCHEMBL8363914 | 0.84 | CALCRL (0.42) | DPP7CTSCMEN1KMT2APRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | claimed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | claimed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | claimed |
| CN-117355341-A | TLR7 and TLR8 agonists for the treatment of cancer and/or infectious diseases | 纽约州立大学研究基金会 | 2024-01-05 | — | — | CN | claimed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | claimed |
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117355341-A | TLR7 and TLR8 agonists for the treatment of cancer and/or infectious diseases | 纽约州立大学研究基金会 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | DPP7 1361/4885CTSC 1982/4885MEN1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.